1380329-87-2

Upstream product

• 110-91-8 morpholine 
• 1380329-77-0 1-methyl-5-(2-phenyl[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid 
• 84249-14-9 2-amino-4-bromopyridine 
• 1202704-61-7 1,2-diamino-4-bromopyridin-1-ium-2,4,6-trimethylbenzenesulfonate 
• 1380331-12-3 7-bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine 
• 81303-65-3 4-(ethoxycarbonyl)-1-methyl-1H-pyrazole-5-carboxylic acid 
• 81303-52-8 ethyl 5-carbamoyl-1-methyl-1H-pyrazole-4-carboxylate 
• 1380330-03-9 1-methyl-5-(2-phenylimidazo[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 1380331-14-5 2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-ylamine 
• 1380331-13-4 (2-phenyl[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamic acid tert-butyl ester 
• 1380329-76-9 1-methyl-5-(2-phenyl[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Palladium-Catalyzed C-N Coupling of Pyrazole Amides with Triazolo- And Imidazopyridine Bromides in Ethanol

An efficient palladium-catalyzed coupling between a pyrazole amide and a heteroaryl bromide was developed to enable the streamlined synthesis of a lead candidate for schizophrenia treatment. Process robustness and scalability were achieved using ethanol a

USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME

Provided herein are methods of treating Tourette Syndrome in a subject in need thereof by administering to the subject compositions comprising a PDE10 inhibitor of Formula (I). Also disclosed are crystalline solid forms of the compound of Formula (I) and

Pd-CATALYZED COUPLING OF PYRAZOLE AMIDES

A novel process for the preparation of imidazo[1,2-a]pyridine compounds of the formula (I), wherein R1 is C1-4-alkoxy or NR4R5 wherein R4 and R5 are independently hydrogen or C1-4-alkyl or R4 and R5, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R2 is C1-4-alkyl, C1-4-alkoxycarbonyl, halogen, phenyl which is optionally substituted with C1-4-alkyl, C1-4-alkoxy or halogen or is NR4R5 wherein R4 and R5 are independently hydrogen or C1-4-alkyl or R4 and R5, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R3 is C1-4-alkyl and X is nitrogen or CH is described. The imidazo[1,2-a]pyridine compounds of the formula (I) are either precursors for active principles or active principles itself, acting as phosphodiesterase (PDE) inhibitors, particularly PDE10 inhibitors which have the potential to treat psychotic disorders like schizophrenia (Int. Patent Publication WO 2012/076430).

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I), wherein R1, R2 , R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. The